Log in

Relevant bibliographies by topics / Allogeneic hematopoietic cell transplantation / Journal articles

To see the other types of publications on this topic, follow the link: Allogeneic hematopoietic cell transplantation.

Journal articles on the topic 'Allogeneic hematopoietic cell transplantation'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Allogeneic hematopoietic cell transplantation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ruutu, Tapani, Christian Koenecke, and Grzegorz W. Basak. "Allogeneic hematopoietic stem cell transplantation and solid organ transplantation in the same patient." Cellular Therapy and Transplantation 4, no. 1-2 (2015): 14–18. http://dx.doi.org/10.18620/1866-8836-2015-4-1-2-14-18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Taskhyngali, Nazgul. "Second hematopoietic stem cell transplantation in miltiple myeloma." Oncology.kz 3, no. 13 (2024): 26–29. https://doi.org/10.56598/2957-6377-2024-3-13-26-29.

Full text

Abstract:

Autologous hematopoietic stem cell transplantation is a standard frontline therapy for multiple myeloma. Performing a second transplant after a relapse of multiple myeloma presents a therapeutic dilemma for doctors. The purpose of this study is to evaluate the effectiveness and feasibility of repeated autologous transplants and haploidentical/allogeneic transplants in patients with multiple myeloma. Methods. A retrospective analysis of the medical histories of patients who underwent transplantation of autologous hematopoietic stem cells with multiple myeloma at the National Cancer Research Cen

APA, Harvard, Vancouver, ISO, and other styles

3

Storb, R., and B. M. Sandmaier. "Nonmyeloablative allogeneic hematopoietic cell transplantation." Haematologica 101, no. 5 (2016): 521–30. http://dx.doi.org/10.3324/haematol.2015.132860.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kai, Shunro, and Hiroshi Hara. "Allogeneic Hematopoietic Stem Cell Transplantation." Therapeutic Apheresis and Dialysis 7, no. 3 (2003): 285–91. http://dx.doi.org/10.1046/j.1526-0968.2003.00053.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bertz, Hartmut. "Allogeneic hematopoietic stem cell transplantation." Current Opinion in Organ Transplantation 6, no. 3 (2001): 259. http://dx.doi.org/10.1097/00075200-200109000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tabbara, Imad A., Kathy Zimmerman, Connie Morgan, and Zeina Nahleh. "Allogeneic Hematopoietic Stem Cell Transplantation." Archives of Internal Medicine 162, no. 14 (2002): 1558. http://dx.doi.org/10.1001/archinte.162.14.1558.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Eida, Elmansorry. "Kinetics of Lymphocytes Reconstitution Post Allogeneic Hematopoietic Stem Cell Transplantation: Two years of Follow-up." Alq J Med App Sci 5, no. 1 (2022): 166–71. https://doi.org/10.5281/zenodo.6374106.

Full text

Abstract:

Background and aims. Allogeneic hematopoietic stem cells transplantation (HSCT) is strong curative treatment for several classes of immunodeficiency, metabolic disorders, and haematopoietic malignancies. Depending on HSCT procedure, thousands of patients could heal from their underlying disease. The ability of hematopoietic stem cells transplantation (HSCT) to cure is affected by variant factors. The objectives of this study were to analyze the kinetics of lymphocyte recovery at different time points after allogeneic hematopoietic stem cells transplantation and to correlate their recovery with

APA, Harvard, Vancouver, ISO, and other styles

8

Akhmedov, M. I., G. A. Klyasova, and E. N. Parovichnikova. "Infectious complications and their contributing risk factors after allogeneic hematopoietic stem cell transplantation." Russian journal of hematology and transfusiology 67, no. 1 (2022): 90–107. http://dx.doi.org/10.35754/0234-5730-2022-67-1-90-107.

Full text

Abstract:

Introduction. Infections are among the most common complications after allogeneic hematopoietic stem cell transplantation.Aim — to provide a literature review on the main characteristics of infectious complications after allogenic hematopoietic stem cell transplantation and risk factors for their development.Main findings. Apart from direct factors such as neutropenia, hypogammaglobulinemia, and lymphopenia, there are indirect transplant-related factors such as conditioning regimen, transplant source, donor type, and graft-versus-host disease prophylaxis associated with higher infectious risk

APA, Harvard, Vancouver, ISO, and other styles

9

González, Marino J., Elena Urizar, Maider Urtaran-Laresgoiti, et al. "Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs." PLOS ONE 16, no. 8 (2021): e0254135. http://dx.doi.org/10.1371/journal.pone.0254135.

Full text

Abstract:

The number of Hematopoietic Stem Cell Transplantations has risen in the past 20 years. The practice of outpatient Hematopoietic Stem Cell Transplantation programs is increasing in an attempt to improve the quality of patient care and reduce the demand for hospital admission. A systematic review of 29 comparative studies between in-hospital and outpatient treatment of Hematopoietic Stem Cell Transplantation, with no restriction by outpatient regime was conducted. This study aims to analyse the current evidence on the effects of the outpatient model on patient-centred outcomes, comparing both in

APA, Harvard, Vancouver, ISO, and other styles

10

Spexoto, Maria Cláudia Bernardes, and Maria Rita Marques de Oliveira. "One-hundred days monitoring patients submitted to hematopoietic stem cell transplantation: Events of metabolic syndrome." Revista de Ciências Médicas 23, no. 1 (2014): 25. http://dx.doi.org/10.24220/2318-0897v23n1a2412.

Full text

Abstract:

ObjectiveThis study assessed early manifestations of metabolic syndrome determinants in patients submitted to hematopoietic stem cell transplantation.MethodsTwenty-seven individuals participated in the study (20 with autologous and 7 with allogeneic hematopoietic stem cell transplantation). Anthropometric variables and biochemical indicators of lipid and glucose metabolism were determined before and 100 days after hematopoietic stem cell transplantation.ResultsThe mean total cholesterol (p=0.086), very low density lipoprotein-cholesterol (p=0.069) and triglycerides (p=0.086) of all patients di

APA, Harvard, Vancouver, ISO, and other styles

11

Xu, Zheng-Li, and Xiao-Jun Huang. "Optimizing Allogeneic Grafts in Hematopoietic Stem Cell Transplantation." Stem Cells Translational Medicine 10, S2 (2021): S41—S47. http://dx.doi.org/10.1002/sctm.20-0481.

Full text

Abstract:

Abstract Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used in the treatment of hematological diseases. It is well known that allogeneic grafts play a key role in predicting transplantation prognosis. Hematopoietic stem cells (HSCs) are a functional part of grafts and are capable of reconstructing hematopoiesis and immunity, but purified HSCs have not been identified or isolated to date. In clinical practice, allogeneic grafts have been optimized to improve transplantation outcomes. The optimized grafts are considered to engraft successfully, reconstruct immunity rap

APA, Harvard, Vancouver, ISO, and other styles

12

Tsakiris, D. A., and G. Stussi. "Late effects on haemostasis after haematopoietic stem cell transplantation." Hämostaseologie 32, no. 01 (2012): 63–66. http://dx.doi.org/10.5482/ha-1184.

Full text

Abstract:

SummaryAllogeneic and autologous hematopoietic stem cell transplantations are important therapeutic options for patients with hematologic disorders. Hemostatic complications are frequent after hematopoietic stem cell transplantation with a considerable morbidity and mortality. The incidence of bleedings and thrombosis is highest in the first few weeks after transplantation, but may also occur later. However, beyond the first year of transplantation only limited data are available. In longterm survivors the risk for premature atherosclerosis increases over time after allogeneic hematopoietic st

APA, Harvard, Vancouver, ISO, and other styles

13

Tsakiris, A., and G. Stussi. "Late effects on haemostasis after haematopoietic stem cell transplantation." Onkologische Welt 03, no. 01 (2012): 12–15. http://dx.doi.org/10.1055/s-0038-1630988.

Full text

Abstract:

SummaryAllogeneic and autologous hematopoietic stem cell transplantations are important therapeutic options for patients with hematologic disorders. Hemostatic complications are frequent after hematopoietic stem cell transplantation with a considerable morbidity and mortality. The incidence of bleedings and thrombosis is highest in the first few weeks after transplantation, but may also occur later. However, beyond the first year of transplantation only limited data are available. In longterm survivors the risk for premature atherosclerosis increases over time after allogeneic hematopoietic st

APA, Harvard, Vancouver, ISO, and other styles

14

Auffermann-Gretzinger, Susanne, Izidore S. Lossos, Tamara A. Vayntrub, et al. "Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients." Blood 99, no. 4 (2002): 1442–48. http://dx.doi.org/10.1182/blood.v99.4.1442.

Full text

Abstract:

Regeneration of hematopoiesis after allogeneic hematopoietic cell transplantation (HCT) involves conversion of the recipient's immune system to donor type. It is likely that distinct cell lineages in the recipient reconstitute at different rates. Dendritic cells (DCs) are a subset of hematopoietic cells that function as a critical component of antigen-specific immune responses because they modulate T-cell activation, as well as induction of tolerance. Mature DCs are transferred with hematopoietic grafts and subsequently arise de novo. Little information exists about engraftment kinetics and tu

APA, Harvard, Vancouver, ISO, and other styles

15

Dansey, Roger D., and Roy D. Baynes. "Nonablative allogeneic hematopoietic stem cell transplantation." Current Opinion in Oncology 13, no. 1 (2001): 27–32. http://dx.doi.org/10.1097/00001622-200101000-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Grunwald, Michael R. "Allogeneic Hematopoietic Cell Transplantation in Septuagenarians." Biology of Blood and Marrow Transplantation 19, no. 9 (2013): 1276–78. http://dx.doi.org/10.1016/j.bbmt.2013.07.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Baron, F., and Y. Beguin. "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation." Journal of Hematotherapy & Stem Cell Research 11, no. 2 (2002): 243–63. http://dx.doi.org/10.1089/152581602753658448.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Schmitz, Norbert, Georg Lenz, and Matthias Stelljes. "Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas." Blood 132, no. 3 (2018): 245–53. http://dx.doi.org/10.1182/blood-2018-01-791335.

Full text

Abstract:

AbstractMature T- and natural killer (NK)–cell neoplasms comprise a group of morphologically, immunophenotypically, molecularly, and clinically heterogeneous disorders with generally unfavorable outcome. Results of first-line chemotherapy are unsatisfactory for the most common T-cell lymphomas (peripheral T-cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; anaplastic large cell lymphomas; anaplastic lymphoma tyrosine kinase–negative) as well as for many other entities. High-dose therapy followed by autologous hematopoietic stem cell transplantation (HSCT) is widely re

APA, Harvard, Vancouver, ISO, and other styles

19

Machado, Celina Angélica Mattos, Angela da Costa Barcellos Marques, Luana Aparecida Alves da Silva, Francisco José Koller, Paulo Ricardo Bittencourt Guimarães, and Luciana Puchalski Kalinke. "Cognitive Impairment and Quality of Life of Patients Subjected to Hematopoietic Stem Cell Transplantation." Aquichan 21, no. 2 (2021): 1–12. http://dx.doi.org/10.5294/aqui.2021.21.2.6.

Full text

Abstract:

Objective: To assess and correlate overall quality of life and the cognitive function of adult patients with hematologic cancer subjected to autologous and allogeneic hematopoietic stem cell transplantations up to three years after treatment. Materials and method: A longitudinal, observational, and analytical study was conducted with 55 patients in a reference hospital in Latin America, from September 2013 to February 2019, with the Quality of Life Questionnaire-Core 30, analyzed with the Spearman’s correlation coefficient and Generalized Linear Mixed Model tests. Results: Overall quality of l

APA, Harvard, Vancouver, ISO, and other styles

20

Zhu, Ying, Tao You, Sicheng Ai, et al. "A Retrospective Comparison of Allogenic and Autologous Hematopoietic Stem Cell Transplantation in Patients with T-Cell Lymphoblastic Lymphoma." Blood 142, Supplement 1 (2023): 7112. http://dx.doi.org/10.1182/blood-2023-185966.

Full text

Abstract:

Background: T-cell lymphoblastic lymphoma (T-LBL) is a rare type of non-Hodgkin's lymphoma accounting for 1%~2% of non-Hodgkin's lymphoma. T-cell lymphoblastic lymphoma is typically found in children and young adults, frequently affecting the mediastinum and bone marrow. It has a poor prognosis and develops quickly. It is anticipated that hematopoietic stem cell transplantation will significantly enhance the prognosis. We conducted a retrospective single center analysis aiming to compare the survival outcomes of autologous and allogeneic hematopoietic stem cell transplantation in patients with

APA, Harvard, Vancouver, ISO, and other styles

21

Blaser, Bradley W., Haesook Kim, Jorge Plutzky, et al. "Hyperlipidemia After Allogeneic Hematopoietic Stem Cell Transplantation." Blood 116, no. 21 (2010): 3457. http://dx.doi.org/10.1182/blood.v116.21.3457.3457.

Full text

Abstract:

Abstract Abstract 3457 An increased incidence of cardiovascular complications has been documented in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Several cross-sectional retrospective studies have described the incidence of cardiovascular risk factors such as lipid elevation late after allo-HSCT, but none have yet considered changes in cholesterol and triglyceride levels within the first two years. We performed a retrospective analysis of all patients who underwent allo-HSCT at the Dana-Farber Cancer Institute from 1998 to 2008 and who survived more than 100 da

APA, Harvard, Vancouver, ISO, and other styles

22

Melikyan, A. L., I. N. Subortseva, E. A. Gilyazitdinova, et al. "The prognostic value of ASXL1 mutation in primary myelofibrosis. Literature review and clinical case description." Terapevticheskii arkhiv 92, no. 7 (2020): 95–99. http://dx.doi.org/10.26442/00403660.2020.07.000788.

Full text

Abstract:

Primary myelofibrosis is a myeloproliferative neoplasm that occurs de novo, characterized by clonal proliferation of stem cells, abnormal expression of cytokines, bone marrow fibrosis, hepatosplenomegaly as a result of extramedullary hematopoiesis, symptoms of tumor intoxication, cachexemia, peripheral blood leukoerythroblastosis, leukemic progression and low survival. Primary myelofibrosis is a chronic incurable disease. The aims of therapy: preventing progression, increasing overall survival, improving quality of life. The choice of therapeutic tactics is limited. Allogenic hematopoietic ste

APA, Harvard, Vancouver, ISO, and other styles

23

Porrata, Luis F. "Autologous Graft-versus-Tumor Effect: Reality or Fiction?" Advances in Hematology 2016 (2016): 1–8. http://dx.doi.org/10.1155/2016/5385972.

Full text

Abstract:

In contrast to allogeneic hematopoietic stem cell transplantation, the current dogma is not an evidence of graft-versus-tumor effect in autologous hematopoietic stem cell transplantation; thus, it is assumed that autologous hematopoietic stem cell transplantation only relies on the high-dose chemotherapy to improve clinical outcomes. However, recent studies argue in favor of the existence of an autologous graft-versus-tumor without the detrimental complications of graft-versus-host disease due to the nonspecific immune response from the infused donor alloreactive immune effector cells in allog

APA, Harvard, Vancouver, ISO, and other styles

24

Sevindik, Ömür Gökmen, İnci Alacacıoğlu, Abdullah Katgı, et al. "Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation." Case Reports in Hematology 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/425410.

Full text

Abstract:

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor cell transplantation, considering the diagnostic uncertainties and lack of established treatment. We report a 43-year-old male patient who was diagnosed as TA-TMA after allogeneic progenitor cell transplantation for a progressive ALK negative anaplastic large cell lymphoma and responded to eculizumab with dramatically improving neurological status and renal function. Rapid neurological and renal recovery achieved after eculizumab could support a possible relationship between

APA, Harvard, Vancouver, ISO, and other styles

25

Annaloro, Claudio, Vittorio Ruggero Zilioli, Nicola Stefano Fracchiolla, et al. "A Long-term Follow-up Analysis in Adult Acute Myeloid Leukemia Patients after Hematopoietic Stem Cell Transplantation." Tumori Journal 91, no. 5 (2005): 388–93. http://dx.doi.org/10.1177/030089160509100502.

Full text

Abstract:

Aims and Background Over the last 17 years, 119 adult acute myeloid leukemia patients have undergone hematopoietic stem cell transplantation at our Center. Study Design Seventy patients in first complete remission received hematopoietic stem cell transplantation (28 allogeneic and 42 autologous HSCT) as late intensification after conventional chemotherapy; 38 patients received allogeneic hematopoietic stem cell transplantation in a more advanced phase. A reference group was built up by collecting 40 acute myeloid leukemia patients who received high-dose cytosine arabinoside as late intensifica

APA, Harvard, Vancouver, ISO, and other styles

26

Ishida, Takashi, Satoshi Takahashi, Chen-Yi Lai, et al. "Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation." Journal of Experimental Medicine 213, no. 9 (2016): 1865–80. http://dx.doi.org/10.1084/jem.20151493.

Full text

Abstract:

Cord blood (CB) is a valuable donor source in hematopoietic cell transplantation. However, the initial time to engraftment in CB transplantation (CBT) is often delayed because of low graft cell numbers. This limits the use of CB. To overcome this cell dose barrier, we modeled an insufficient dose CBT setting in lethally irradiated mice and then added hematopoietic stem/progenitor cells (HSCs/HPCs; HSPCs) derived from four mouse allogeneic strains. The mixture of HSPCs rescued recipients and significantly accelerated hematopoietic recovery. Including T cells from one strain favored single-donor

APA, Harvard, Vancouver, ISO, and other styles

27

Imamura, Masahiro. "Impaired Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation: Its Pathogenesis and Potential Treatments." Hemato 2, no. 1 (2021): 43–63. http://dx.doi.org/10.3390/hemato2010002.

Full text

Abstract:

Impaired hematopoiesis is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Bone marrow aplasia and peripheral cytopenias arise from primary and secondary graft failure or primary and secondary poor graft function. Chimerism analysis is useful to discriminate these conditions. By determining the pathogenesis of impaired hematopoiesis, a timely and appropriate treatment can be performed. Hematopoietic system principally consists of hematopoietic stem cells and bone marrow microenvironment termed niches. Abnormality in hematopoietic stem and progenitor

APA, Harvard, Vancouver, ISO, and other styles

28

Saad, Ayman, Marcos de Lima, Sarah Anand, et al. "Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network 18, no. 5 (2020): 599–634. http://dx.doi.org/10.6004/jnccn.2020.0021.

Full text

Abstract:

Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient’s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to

APA, Harvard, Vancouver, ISO, and other styles

29

Cutler, Corey. "Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome." Hematology 2010, no. 1 (2010): 325–29. http://dx.doi.org/10.1182/asheducation-2010.1.325.

Full text

Abstract:

Abstract Transplantation is the only known cure for myelodysplastic syndrome (MDS). While some comparative analyses have demonstrated early transplantation to be the preferred strategy for all MDS patients, many of these analyses are biased. Using newly identified prognostic factors and models, a rational approach to transplantation can be undertaken. Factors such as transfusion dependency, cytogenetics, medical comorbidity, and World Health Organization (WHO) histologic subtype should all be considered when deciding on the role of transplantation for the MDS patient. Unresolved issues in tran

APA, Harvard, Vancouver, ISO, and other styles

30

Schneidawind, Dominik, Katharina Oehrlein, Katja C. Weisel, Christoph Faul, Lothar Kanz, and Wolfgang A. Bethge. "Salvage Allogeneic Hematopoietic Cell Transplantation for Relapsed or Progressive Multiple Myeloma After Autologous Hematopoietic Cell Transplantation." Blood 120, no. 21 (2012): 2043. http://dx.doi.org/10.1182/blood.v120.21.2043.2043.

Full text

Abstract:

Abstract Abstract 2043 Introduction: Limited data exist about allogeneic hematopoietic cell transplantation (HCT) as salvage treatment of relapsed or progressive multiple myeloma (MM) after autologous HCT in the era of proteasome inhibitors and next-generation immunomodulatory drugs. Methods: Retrospective analysis of 27 consecutive adult patients (median age 52 years, range 38–67, f=7, m=20) with relapsed (n=7) or progressive (n=20) MM after single (n=11) or tandem (n=16) autologous HCT treated at our institution from 2001 to 2012 with allogeneic HCT as salvage treatment. Conditioning regimen

APA, Harvard, Vancouver, ISO, and other styles

31

Enrico, Santinelli, Cerretti Raffaella, De Angelis Gottardo, et al. "Allogeneic hematopoietic cell transplantation to treat two synchronous hematologic malignancies." Journal of Stem Cell Therapy and Transplantation 6, no. 1 (2022): 005–7. http://dx.doi.org/10.29328/journal.jsctt.1001025.

Full text

Abstract:

Allogeneic hematopoietic cell transplantation often represents the only solution for several poor-prognosis hematologic malignancies. The curative strategy for patients with synchronous hematologic disorders is always difficult and, in most cases, ineffective. Herein, we report an unusual case of synchronous hematologic disorders successfully treated with an “ad-hoc” conditioning regimen followed by allogeneic hematopoietic cell transplantation.

APA, Harvard, Vancouver, ISO, and other styles

32

El, Farra, Borivoj Sekulic, Ivana Urosevic, Stevan Popovic, Dusan Pejin, and Aleksandar Savic. "Allogeneic hematopoietic stem cell transplantation at the Clinical Center of Vojvodina." Medical review 70, suppl. 1 (2017): 13–17. http://dx.doi.org/10.2298/mpns17s1013e.

Full text

Abstract:

Introduction. Allogenic hematopoietic stem cell transplantation is the best therapeutic option for the treatment of some inherited and acquired diseases of the hematopoietic system as well as various hematological malignancies. Material and Methods. The study was conducted as a retrospective analysis of 35 patients who underwent allogenic hematopoietic stem cell transplantation at the Clinic of Hematology, Clinical Center of Vojvodina. Results. In a group of 35 patients with median age 33 years, 13 patients had acute myeloid leukemia, one patient had acute lymphoblastic leukemia, nine had chro

APA, Harvard, Vancouver, ISO, and other styles

33

Baldomero, Helen, Mahmoud Aljurf, Luis Fernando Bouzas, et al. "Global Trends in Hematopoietic Cell Transplantation." Blood 120, no. 21 (2012): 3143. http://dx.doi.org/10.1182/blood.v120.21.3143.3143.

Full text

Abstract:

Abstract Abstract 3143 Hematopoietic cell transplantation (HCT) is the treatment of choice for many patients with malignant and non-malignant disorders. Transplant practices have evolved allowing patients previously not otherwise candidates to receive this procedure. Activity surveys and registries play an essential role in the success of HCT, by tracking activities, identifying areas of need and through clinical research to continue improving patient outcome. Because of the need of matched donors, ethnic characteristics and legal requirements HCT has acquired a global dimension. In the curren

APA, Harvard, Vancouver, ISO, and other styles

34

Storek, J. "B-cell immunity after allogeneic hematopoietic cell transplantation." Cytotherapy 4, no. 5 (2002): 423–24. http://dx.doi.org/10.1080/146532402320776026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Cassaday, Ryan D., and Ajay K. Gopal. "Allogeneic hematopoietic cell transplantation in mantle cell lymphoma." Best Practice & Research Clinical Haematology 25, no. 2 (2012): 165–74. http://dx.doi.org/10.1016/j.beha.2012.04.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Shilling, Heather G., Karina L. McQueen, Nathalie W. Cheng, Judith A. Shizuru, Robert S. Negrin, and Peter Parham. "Reconstitution of NK cell receptor repertoire followingHLA-matched hematopoietic cell transplantation." Blood 101, no. 9 (2003): 3730–40. http://dx.doi.org/10.1182/blood-2002-08-2568.

Full text

Abstract:

Interactions between killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I ligands influence development of natural killer (NK) cell repertoire and response to infection, cancer, and allogeneic tissue. As KIRs and HLA class I molecules are highly polymorphic, clinical allogeneic hematopoietic cell transplantation is predicted to frequently involve KIRmismatch, and thus to provide a unique system for study of human NK cell receptor repertoire development. Eighteen leukemia patients undergoing HLA-matched transplantation and their donors were analyzed for KIR geno

APA, Harvard, Vancouver, ISO, and other styles

37

Vujic, Dragana, Zeljko Zecevic, Marija Simic, et al. "Pediatric hematopoietic stem cell transplantation in Serbia - 25 years of experience." Medical review 75, Suppl. 1 (2022): 50–53. http://dx.doi.org/10.2298/mpns22s1050v.

Full text

Abstract:

The first allogeneic identical sibling donor hematopoietic stem cell transplantation at the Institute for Mother and Child Health Care of Serbia ?Dr. Vukan Cupic? (Institute) was performed in the seventies of the last century. Almost twenty years later, the first allogeneic transplant from sibling haploidentical donor was performed in an infant suffering from severe combined immunodeficiency. After several years of efforts, the bone marrow transplant unit was opened in April 1997 at the Institute. Over the 25 years, the transplant team performed 360 hematopoietic stem cell transplantations, 17

APA, Harvard, Vancouver, ISO, and other styles

38

Schwabkey, Zaker I., and Robert R. Jenq. "Microbiome Anomalies in Allogeneic Hematopoietic Cell Transplantation." Annual Review of Medicine 71, no. 1 (2020): 137–48. http://dx.doi.org/10.1146/annurev-med-052918-122440.

Full text

Abstract:

The microbiome is an integrated part of the human body that can modulate a variety of disease processes and affect prognosis, treatment response, complications, and outcomes. The importance of allogeneic hematopoietic cell transplantation in cancer treatment has resulted in extensive investigations on the interaction between the microbiome and this treatment modality. These investigations are beginning to lead to clinical trials of microbiome-targeted interventions. Here we review some of these discoveries and describe strategies being investigated to manipulate the microbiome for favorable ou

APA, Harvard, Vancouver, ISO, and other styles

39

Atalla, Angelo, Abrahão Elias Hallack Neto, Denise Bittencourt Siqueira, and Gabriela Cumani Toledo. "Allogeneic hematopoietic stem cell transplantation in mycosis fungoides." Anais Brasileiros de Dermatologia 88, no. 6 suppl 1 (2013): 216–19. http://dx.doi.org/10.1590/abd1806-4841.20132365.

Full text

Abstract:

Mycosis Fungoides is typically an indolent disease in early stages. However, approximately 30% of patients have advanced staged disease at presentation and 20% will develop it at some time. These patients have a poorer prognosis with a median survival of 2-4 years. The only curative option for mycosis fungoides may be hematopoietic allogeneic stem cell transplantation. We report the case of a patient with mycosis fungoides in an advanced stage (IIB), refractory to treatment options. She underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT). The patient remains in complete re

APA, Harvard, Vancouver, ISO, and other styles

40

Dean, Robert M., and Michael R. Bishop. "Allogeneic Hematopoietic Stem Cell Transplantation for Lymphoma." Clinical Lymphoma 4, no. 4 (2004): 238–49. http://dx.doi.org/10.3816/clm.2004.n.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Kim, Hee-Je. "HLA Mismatched Allogeneic Hematopoietic Stem Cell Transplantation." Korean Journal of Hematology 42, no. 1 (2007): 1. http://dx.doi.org/10.5045/kjh.2007.42.1.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Barabanshchikova, MV, EV Morozova, VV Baykov, et al. "Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis." Clinical oncohematology 9, no. 3 (2016): 279–86. http://dx.doi.org/10.21320/2500-2139-2016-9-3-279-286.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Lin, Richard J., and Andrew S. Artz. "Allogeneic hematopoietic cell transplantation for older patients." Hematology 2021, no. 1 (2021): 254–63. http://dx.doi.org/10.1182/hematology.2021000257.

Full text

Abstract:

Abstract Hematologic malignances are more common and often higher risk in older patients. Allogeneic hematopoietic cell transplantation (alloHCT) best enables long-term disease control for patients with poor risk or relapsed/refractory hematologic malignancies such as acute myeloid leukemia, myelodysplastic syndromes, or myelofibrosis. Rates of alloHCT among older patients, while still relatively low compared with younger patients, have risen sharply over the past decade. Accumulating evidence supports alloHCT for patients ≥60 years of age relative to non-HCT therapies based on improved overal

APA, Harvard, Vancouver, ISO, and other styles

44

Arnaout, Karim, Nihar Patel, Maneesh Jain, Joelle El-Amm, Farah Amro, and Imad A. Tabbara. "Complications of Allogeneic Hematopoietic Stem Cell Transplantation." Cancer Investigation 32, no. 7 (2014): 349–62. http://dx.doi.org/10.3109/07357907.2014.919301.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Lee, Gyeong-Won, Je-Hwan Lee, Seong-Jun Choi, et al. "Hemorrhagic Cystitis Following Allogeneic Hematopoietic Cell Transplantation." Journal of Korean Medical Science 18, no. 2 (2003): 191. http://dx.doi.org/10.3346/jkms.2003.18.2.191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Rondelli, D. "Allogeneic hematopoietic stem cell transplantation for myelofibrosis." Haematologica 93, no. 10 (2008): 1449–50. http://dx.doi.org/10.3324/haematol.13801.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Worel, N., and P. Kalhs. "AB0-incompatible allogeneic hematopoietic stem cell transplantation." Haematologica 93, no. 11 (2008): 1605–7. http://dx.doi.org/10.3324/haematol.2008.001057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Robinson, Tracy, and Erin Streu. "Malakoplakia After Allogeneic Hematopoietic Stem Cell Transplantation." Oncology Nursing Forum 42, no. 5 (2015): 558–61. http://dx.doi.org/10.1188/15.onf.558-561.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Tamura, Shinichi, Toshihiko Imamura, Takayo Urata, et al. "Allogeneic Hematopoietic Cell Transplantation for Dyskeratosis Congenita." Journal of Pediatric Hematology/Oncology 39, no. 7 (2017): e394-e398. http://dx.doi.org/10.1097/mph.0000000000000844.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Khera, Nandita, Barry Storer, Brenda M. Sandmaier, Michael K. Chapko, and Stephanie J. Lee. "Costs of Second Allogeneic Hematopoietic Cell Transplantation." Transplantation Journal 96, no. 1 (2013): 108–15. http://dx.doi.org/10.1097/tp.0b013e318294caf1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!